Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Mar;196(3):286-288.
doi: 10.1007/s00066-019-01574-y.

[Ribociclib in combination with endocrine therapy improves overall survival of pre-/perimenopausal breast cancer patients]

[Article in German]
David Krug  1 , Alexander Fabian  2 , Jürgen Dunst  2
Affiliations
Comment

[Ribociclib in combination with endocrine therapy improves overall survival of pre-/perimenopausal breast cancer patients]

[Article in German]
David Krug et al. Strahlenther Onkol. 2020 Mar.

Erratum in

No abstract available

PubMed Disclaimer

Comment on

  • Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
    Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva-Vazquez R, Jung KH, Chakravartty A, Hughes G, Gounaris I, Rodriguez-Lorenc K, Taran T, Hurvitz S, Tripathy D. Im SA, et al. N Engl J Med. 2019 Jul 25;381(4):307-316. doi: 10.1056/NEJMoa1903765. Epub 2019 Jun 4. N Engl J Med. 2019. PMID: 31166679 Clinical Trial.

References

    1. Thill M, Jackisch C, Janni W, et al. AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2019. Breast Care. 2019;14:1–9. doi: 10.1159/000500999. - DOI - PMC - PubMed
    1. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–439. doi: 10.1016/S1470-2045(15)00613-0. - DOI - PubMed
    1. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N Engl J Med. 2019;380:1929–1940. doi: 10.1056/NEJMoa1813904. - DOI - PubMed
    1. Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a Germline BRCA mutation. N Engl J Med. 2017;377:523–533. doi: 10.1056/NEJMoa1706450. - DOI - PubMed
    1. Mehta RS, Barlow WE, Albain KS, et al. Overall survival with Fulvestrant plus Anastrozole in metastatic breast cancer. N Engl J Med. 2019;380:1226–1234. doi: 10.1056/NEJMoa1811714. - DOI - PMC - PubMed